Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KETAMINE HYDROCHLORIDE vs DIPRIVAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Noncompetitive NMDA receptor antagonist; also interacts with opioid receptors, monoaminergic receptors, and voltage-gated calcium channels.
Propofol potentiates GABA-A receptor activity, leading to rapid sedation and hypnosis by enhancing chloride conductance and neuronal hyperpolarization.
Induction and maintenance of general anesthesia,Sedation,Analgesic for acute pain,Treatment-resistant depression (off-label),Status epilepticus (off-label)
Induction and maintenance of general anesthesia,Sedation for intubated, mechanically ventilated patients in intensive care units,Monitored anesthesia care (MAC) sedation,Treatment of refractory status epilepticus (off-label),Procedural sedation (off-label)
Induction: 1-2 mg/kg IV, 0.5-1 mg/kg/min IV infusion for maintenance. Dissociative sedation: 1-1.5 mg/kg IV or 3-4 mg/kg IM. Pain management: 0.1-0.5 mg/kg IV bolus followed by 0.1-0.4 mg/kg/h IV infusion.
Induction: 2-2.5 mg/kg IV bolus; maintenance: 25-75 mcg/kg/min IV infusion.
Terminal elimination half-life of ketamine is 2.5–3 hours; norketamine half-life is approximately 4 hours. Context: Prolonged elimination may occur with hepatic impairment or high-dose infusions.
Terminal elimination half-life: 4-7 hours (with context of context-sensitive half-life increasing after prolonged infusion).
Hepatic via CYP2B6 and CYP3A4; major metabolite norketamine.
Primarily hepatic conjugation to inactive metabolites (propofol glucuronide), with minor metabolism via CYP2B6 and CYP2C9 to 4-hydroxypropofol.
Ketamine is primarily metabolized in the liver via N-demethylation to norketamine. Renal excretion accounts for approximately 90% of the dose, with 4% as unchanged drug, 16% as norketamine, and the remainder as conjugated metabolites. Fecal excretion is minimal (<5%).
Renal (approximately 88% as metabolites, <1% unchanged); fecal (approximately 2%); other (10% as metabolites via other routes).
Approximately 47% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
95-99% bound, primarily to albumin.
Volume of distribution is 3–5 L/kg, indicating extensive tissue distribution and accumulation in lipid-rich tissues (e.g., brain, adipose).
2-10 L/kg (large Vd indicating extensive tissue distribution).
Oral: 17–20% (extensive first-pass metabolism); Intranasal: 45–50%; IM: 93%; Rectal: 25–50%; IV: 100%.
Intravenous: 100%; not available orally due to extensive first-pass metabolism.
No specific GFR-based dose adjustment is required. Use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of active metabolite norketamine; monitor for prolonged effects.
No adjustment required; propofol is not significantly renally eliminated.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 25-50% and titrate to effect. Child-Pugh Class C: Contraindicated or use with extreme caution; reduce dose by 50-75% and monitor closely.
No specific Child-Pugh based guidelines; use lower doses due to impaired clearance, especially in cirrhosis.
Induction: 1-2 mg/kg IV, 3-4 mg/kg IM. Maintenance: 0.5-1 mg/kg IV or IM as needed. Procedural sedation: 0.5-1 mg/kg IV, may repeat. Continuous infusion: 0.2-0.5 mg/kg/h. Maximum single dose: 2 mg/kg IV, 4 mg/kg IM.
Induction: 2.5-3.5 mg/kg IV bolus; maintenance: 125-300 mcg/kg/min IV infusion. Not approved for ICU sedation in <16 years.
Reduce initial dose by 20-50% due to decreased clearance and increased sensitivity. Titrate slowly to effect. Monitor for cardiovascular and cognitive adverse effects closely.
Reduce induction dose to 1-1.5 mg/kg IV bolus and maintenance infusion to 20-50 mcg/kg/min IV due to increased sensitivity and decreased clearance.
None.
Propofol should be administered only by persons trained in the administration of general anesthesia and not involved in the conduct of the surgical/diagnostic procedure. Patients should be continuously monitored for early signs of hypotension, bradycardia, apnea, airway obstruction, and oxygen desaturation. For sedation of intubated, mechanically ventilated patients in the ICU, propofol should be used with caution in patients with increased intracranial pressure or impaired cerebral circulation.
Emergence reactions (hallucinations, confusion),Hemodynamic instability (hypertension, tachycardia),Increased intracranial pressure,Respiratory depression,Urinary tract toxicity with chronic use
Risk of hypotension and bradycardia, especially in elderly or hypovolemic patients,Respiratory depression and apnea requiring airway management,Propofol infusion syndrome (PRIS): metabolic acidosis, rhabdomyolysis, renal failure, cardiac failure, especially with prolonged high-dose infusions,Hypertriglyceridemia; monitor lipids with prolonged use,Risk of pancreatitis,Use with caution in patients with epilepsy; may increase seizure risk during withdrawal,May cause green discoloration of urine, hair, or nails
Hypersensitivity to ketamine,Conditions where elevated blood pressure is dangerous (e.g., aneurysms, uncontrolled hypertension),Severe coronary artery disease,Increased intracranial pressure (relative)
Hypersensitivity to propofol or any component of the formulation,Hypersensitivity to eggs, egg products, soybeans, or soy products (due to lipid vehicle),Patients with severe lipid metabolism disorders (e.g., hyperlipidemia),Not recommended for general anesthesia in patients with increased intracranial pressure or impaired cerebral circulation unless benefits outweigh risks
No significant food interactions; grapefruit juice may increase ketamine levels via CYP3A4 inhibition, but clinical relevance is unclear; avoid alcohol consumption due to additive sedative effects.
No specific food interactions; however, propofol emulsion contains soybean oil and egg lecithin, so avoid in patients with egg or soy allergies. The emulsion can be contaminated if bottle is reused; discard after single use. No dietary restrictions required for administration.
Ketamine crosses the placenta. First trimester: Limited human data, animal studies show developmental toxicity at high doses; avoid unless essential. Second/Third trimester: Use only for indicated procedures (e.g., surgical anesthesia, procedural sedation) as maternal hypoxia may risk fetus; potential for neonatal respiratory depression if used near delivery. Neonatal effects: Possible altered neurodevelopment; consider risk-benefit.
Propofol (DIPRIVAN) is Pregnancy Category B. Animal studies at clinical doses did not show teratogenicity. Use in first trimester only if clearly needed. During second and third trimesters, propofol crosses the placenta and may cause neonatal respiratory depression and neurobehavioral depression. Risk of fetal acidosis and bradycardia. No major teratogenic effects reported in human studies, but limited data.
Ketamine enters breast milk; milk-to-plasma ratio approximately 0.8-1.5. Limited data; low absolute dose (<2% maternal weight-adjusted dose). Caution with repeated high doses; monitor infant for sedation, feeding difficulties. American Academy of Pediatrics: compatible with breastfeeding after single doses.
Propofol is excreted into breast milk in low concentrations. M/P ratio not established. Due to low oral bioavailability, risk to infant is minimal. However, caution is advised due to potential CNS depression in neonates. The manufacturer recommends discontinuing breastfeeding for 24 hours after administration.
Pregnancy may alter pharmacokinetics: increased volume of distribution may require higher initial doses; decreased plasma protein binding may increase free fraction. However, standard dosing guidelines for procedures apply; titrate to effect. Use lowest effective dose due to potential neurotoxicity. Caution with repeated use or long infusions.
Pharmacokinetic changes in pregnancy include increased volume of distribution and clearance, particularly in the third trimester. No specific dose adjustment guidelines; clinical response and patient condition determine dosing. Reduced doses may be required due to increased sensitivity to propofol in pregnancy.
Ketamine produces dissociative anesthesia with preserved airway reflexes and respiratory drive at sub-anesthetic doses; monitor for emergence reactions (hallucinations, delirium) especially in adults; co-administer a benzodiazepine to reduce psychotomimetic effects; use with caution in patients with hypertension, tachycardia, or increased intracranial pressure; can cause increased secretions, consider an anticholinergic like glycopyrrolate; analgesic doses are sub-dissociative (0.1-0.5 mg/kg IV); contraindicated in patients with severe coronary artery disease or recent cerebrovascular accident.
DIPRIVAN (propofol) causes pain on injection, especially in small veins; pretreatment with lidocaine or use of a larger vein can mitigate. It is formulated as a lipid emulsion containing soybean oil and egg lecithin, thus contraindicated in patients with egg or soybean allergies. Propofol can cause profound hypotension and respiratory depression; ensure airway equipment and vasopressors are immediately available. The infusion syndrome (PRIS) is rare but lethal, characterized by metabolic acidosis, rhabdomyolysis, and cardiac failure; avoid prolonged high-dose infusions (>5 mg/kg/hr for >48 hours).
You may feel detached from your body or have unusual dreams during recovery; this is normal and temporary.,Do not drive or operate machinery for 24 hours after receiving ketamine.,Avoid alcohol and other sedatives for at least 24 hours after treatment.,Report any hallucinations, confusion, or difficulty breathing to your healthcare provider immediately.,For nasal spray (esketamine), follow instructions for administration and avoid eating or drinking for 30 minutes after use.
You will be monitored continuously during and after administration due to risk of low blood pressure and slowed breathing.,You may feel a burning or stinging sensation at the injection site; inform your healthcare provider if it persists.,Do not drive or operate machinery for at least 24 hours after receiving propofol due to residual sedation.,Inform your medical team if you have allergies to eggs, soy, or sesame seeds.,Propofol is not intended for home use; it is only administered in a supervised medical setting.
"Butabarbital, a barbiturate, induces cytochrome P450 (CYP) enzymes, enhancing the hepatic metabolism of ketamine, a dissociative anesthetic primarily metabolized by CYP3A4 and CYP2B6. This interaction reduces ketamine's systemic exposure and anesthetic efficacy, potentially leading to suboptimal sedation or anesthesia. Additionally, concurrent use may increase the risk of respiratory depression and hypotension due to additive central nervous system (CNS) depressant effects."
"The combination of ketamine and diamorphine can lead to additive central nervous system (CNS) depression and respiratory depression, increasing the risk of hypoxia, sedation, and respiratory arrest. Ketamine, an NMDA receptor antagonist, enhances opioid-induced analgesia but also potentiates the adverse effects of diamorphine, including hypotension and bradycardia. Patients may experience profound sedation, confusion, and cardiovascular instability, particularly at higher doses or in opioid-naive individuals."
"Ketamine, an NMDA receptor antagonist, may inhibit cytochrome P450 3A4 (CYP3A4) activity, which is responsible for the 25-hydroxylation of cholecalciferol (vitamin D3) to calcidiol (25-hydroxyvitamin D). This inhibition can reduce the conversion of cholecalciferol to its active form, potentially leading to decreased vitamin D levels and impaired calcium homeostasis. Clinically, this may increase the risk of vitamin D deficiency, contributing to bone demineralization, hypocalcemia, or secondary hyperparathyroidism in patients receiving long-term or high-dose ketamine therapy."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KETAMINE HYDROCHLORIDE vs DIPRIVAN, answered by our medical review team.
KETAMINE HYDROCHLORIDE is a General Anesthetic that works by Noncompetitive NMDA receptor antagonist; also interacts with opioid receptors, monoaminergic receptors, and voltage-gated calcium channels.. DIPRIVAN is a General Anesthetic that works by Propofol potentiates GABA-A receptor activity, leading to rapid sedation and hypnosis by enhancing chloride conductance and neuronal hyperpolarization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KETAMINE HYDROCHLORIDE and DIPRIVAN depend on the specific clinical indication. These are both General Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KETAMINE HYDROCHLORIDE is: Induction: 1-2 mg/kg IV, 0.5-1 mg/kg/min IV infusion for maintenance. Dissociative sedation: 1-1.5 mg/kg IV or 3-4 mg/kg IM. Pain management: 0.1-0.5 mg/kg IV bolus followed by 0.1-0.4 mg/kg/h IV infusion.. The standard adult dose of DIPRIVAN is: Induction: 2-2.5 mg/kg IV bolus; maintenance: 25-75 mcg/kg/min IV infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KETAMINE HYDROCHLORIDE and DIPRIVAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KETAMINE HYDROCHLORIDE is classified as Category C. Ketamine crosses the placenta. First trimester: Limited human data, animal studies show developmental toxicity at high doses; avoid unless essential. Second/Third trimester: Use on. DIPRIVAN is classified as Category C. Propofol (DIPRIVAN) is Pregnancy Category B. Animal studies at clinical doses did not show teratogenicity. Use in first trimester only if clearly needed. During second and third tr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.